J. Goldman & Co LP Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

J. Goldman & Co LP cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 81.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,036 shares of the biopharmaceutical company's stock after selling 34,751 shares during the quarter. J. Goldman & Co LP's holdings in TG Therapeutics were worth $242,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in shares of TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares in the last quarter. Franklin Resources Inc. raised its stake in TG Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock worth $2,945,000 after buying an additional 4,756 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after buying an additional 725,371 shares during the period. Brookstone Capital Management boosted its position in TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after acquiring an additional 624 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of TG Therapeutics by 52.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 2,803 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $34.99 on Tuesday. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of -349.87 and a beta of 2.21. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock's 50-day simple moving average is $38.90 and its 200-day simple moving average is $33.79.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the previous year, the firm posted ($0.07) EPS. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TGTX has been the topic of a number of recent research reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.